摘要
目的:探讨清纤方抗肝纤维化的治疗机制。方法:利用CCl4制备肝纤维化Wistar大鼠模型,分为正常组、模型组、清纤方组、秋水仙碱组。治疗8周后,用HE和Masson染色观察肝纤维化的形成,免疫组化检测Ⅰ、Ⅲ胶原,RT-PCR检测肝组织中转化生长因子β1(TGF-β1)mRNA的表达。结果:Ⅰ、Ⅲ胶原和TGF-β1mRNA的表达在治疗组均明显减少。结论:清纤方能有效减轻肝纤维化大鼠的肝脏损伤及纤维化程度,其机制可能与抑制肝内TGF-1β的表达有关。
Objective:To explore the therapeutic mechanism of Qingxianfang for anti-hepatic fibrosis.Method: Hepatic fibrosis of Wistar rat was established by injecting CCl4 and divided them into groups marked "model","Qingxianfang" and "colchicines".Another group of normal rat was used as /!control/.After eight weeks of treatment,an observation of hepatic fibrosis is carried on by using HE and Masson pigmentation,immunohistochemistry and detecting the expression of collagen type I,type Ⅲ.TGF-β1 mRNA expression in hepatic tissue was determined by RT-PCR.Result: The collagen type Ⅰ,type Ⅲ and the expression of TGF-β1 mRNA reduced significantly in treatment group.Conclusion: Qingxianfang is effective for easing the liver damage and hepatic fibrosis condition in rats.The mechanism may be relative to the restraining of TGF-β1 expression in the liver.
出处
《中国实验方剂学杂志》
CAS
北大核心
2009年第12期75-78,共4页
Chinese Journal of Experimental Traditional Medical Formulae